Literature DB >> 30191059

Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.

Francesco Tovoli1,1, Matteo Renzulli2,2, Alessandro Granito1,1, Rita Golfieri2,2, Luigi Bolondi1,1.   

Abstract

Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic assessment of its biological activity is a disputed matter as at least five different criteria have been proposed. In this review, we describe the characteristic of the Response Evaluation Criteria In Solid Tumors (RECIST), European Association for the Study of The Liver (EASL), modified RECIST (mRECIST), Response Evaluation Criteria In the Cancer of the Liver (RECICL) and Choi criteria. The existing comparative studies are reported together with recent pieces of evidence, analyzing the reasons behind the split between recommendations of the scientific societies and regulatory agencies. Future perspectives in the wake of the impending results of the immunotherapy trials are also discussed.

Entities:  

Keywords:  Choi; RECICL; RECIST; hepatocellular carcinoma; immunotherapy; mRECIST; nivolumab; regorafenib; sorafenib

Year:  2017        PMID： 30191059      PMCID： PMC6096444          DOI： 10.2217/hep-2017-0018

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  34 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.

Authors:  Wayne L Monsky; Armando S Garza; Isaac Kim; Shaun Loh; Tzu-Chun Lin; Chin-Shang Li; Jerron Fisher; Parmbir Sandhu; Vishal Sidhar; Abhijit J Chaudhari; Frank Lin; Larry-Stuart Deutsch; Ramsey D Badawi
Journal:  Cardiovasc Intervent Radiol       Date:  2010-08-04       Impact factor: 2.740

3.  Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version).

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Shoji Kubo; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Takamichi Murakami; Masumi Kadoya; Norihiro Kokudo
Journal:  Hepatol Res       Date:  2015-08-04       Impact factor: 4.288

4.  mRECIST for systemic therapies: More evidence is required before recommendations can be made.

Authors:  Julien Edeline; Daniel Palmer; Jean-Frédéric Blanc; Boris Campillo-Gimenez; Philippe Merle; Tim Meyer
Journal:  J Hepatol       Date:  2017-03-16       Impact factor: 25.083

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

Review 7.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz
Journal:  Oncologist       Date:  2007-04

8.  mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).

Authors:  H J Prajapati; J R Spivey; S I Hanish; B F El-Rayes; J S Kauh; Z Chen; H S Kim
Journal:  Ann Oncol       Date:  2012-12-05       Impact factor: 32.976

9.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

10.  Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Authors:  Sadahisa Ogasawara; Fumihiko Kanai; Yoshihiko Ooka; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Tetsuhiro Chiba; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2013-02-12       Impact factor: 9.029
View more
  10 in total

Review 1.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

2.  A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles.

Authors:  Yuji Eso; Shigeharu Nakano; Masako Mishima; Soichi Arasawa; Eriko Iguchi; Haruhiko Takeda; Atsushi Takai; Ken Takahashi; Hiroshi Seno
Journal:  Quant Imaging Med Surg       Date:  2021-06

Review 3.  Experience with regorafenib in the treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Antonella Forgione; Sara Marinelli; Matteo Renzulli; Luca Ielasi; Vito Sansone; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  Therap Adv Gastroenterol       Date:  2021-05-28       Impact factor: 4.409

4.  Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

Authors:  Ruwanthi Kolamunnage-Dona; Sarah Berhane; Harry Potts; Edward H Williams; James Tanner; Tobias Janowitz; Matthew Hoare; Philip Johnson
Journal:  J Hepatol       Date:  2021-05-27       Impact factor: 30.083

5.  Changing TACTICS in intermediate HCC: TACE plus sorafenib.

Authors:  Pompilia Radu; Jean-François Dufour
Journal:  Gut       Date:  2020-03-13       Impact factor: 23.059

Review 6.  Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors.

Authors:  Suemi Yabuta; Yoshihiro Shidoji
Journal:  Hepat Oncol       Date:  2019-06-05

Review 7.  Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.

Authors:  Valerie J W Tong; Vishal G Shelat; Yew Kuo Chao
Journal:  J Clin Transl Res       Date:  2021-11-06

Review 8.  Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Authors:  Alessandro Granito; Sara Marinelli; Antonella Forgione; Matteo Renzulli; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  J Hepatocell Carcinoma       Date:  2021-05-26

9.  Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.

Authors:  Keara English; N Patrik Brodin; Viswanathan Shankar; Shaoyu Zhu; Nitin Ohri; Yosef S Golowa; Jacob Cynamon; Sarah Bellemare; Andreas Kaubisch; Milan Kinkhabwala; Shalom Kalnicki; Madhur K Garg; Chandan Guha; Rafi Kabarriti
Journal:  JAMA Netw Open       Date:  2020-11-02

10.  Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.

Authors:  Xinhua Zou; Wenzhe Fan; Miao Xue; Jiaping Li
Journal:  Cancer Manag Res       Date:  2021-05-18       Impact factor: 3.989
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.